RenovoRx's TAMP Platform Shows Promise in Locally Advanced Pancreatic Cancer

  • RenovoRx published a peer-reviewed case series in Case Reports in Oncology highlighting the TAMP™ Platform's potential to improve chemotherapeutic delivery for locally advanced pancreatic cancer.
  • The study involved two patients with locally advanced pancreatic cancer who demonstrated tumor treatment response with reductions in CA 19-9 and favorable changes on imaging.
  • Hackensack Meridian Health Jersey Shore University Medical Center has been using the TAMP Platform with the RenovoCath device in its oncology program for over a year.
  • RenovoRx generated approximately $1.1 million in RenovoCath sales in 2025 and $909,000 in the second quarter of 2026.
  • The company expects topline data readout from the Phase III TIGeR-PaC trial in the second half of 2027.

RenovoRx's peer-reviewed publication underscores the potential of its TAMP™ Platform to enhance targeted chemotherapy delivery for locally advanced pancreatic cancer, a notoriously difficult-to-treat condition. The company's focus on expanding the use of RenovoCath in high-volume cancer centers aligns with broader industry trends toward precision oncology. With the Phase III TIGeR-PaC trial nearing completion, the next critical phase will be translating clinical data into commercial success and regulatory approval.

Clinical Validation
How the peer-reviewed publication will influence the adoption of the TAMP™ Platform in clinical settings.
Commercial Expansion
Whether RenovoRx can sustain its revenue growth by expanding the number of medical institutions using RenovoCath.
Regulatory Milestones
The pace at which the Phase III TIGeR-PaC trial results will impact the regulatory approval process for the IAG combination product.